MADRID, 8 Ago. (EUROPA PRESS) –
The Danish pharmaceutical Novo Nordisk has closed the session this Tuesday with a revaluation of 17.26% of its shares, after the company has announced that the SELECT clinical trial confirms that semaglutide, which it markets under the name ‘Wegovy’, reduces the risk of adverse cardiovascular events by 20%.
In this regard, Novo Nordisk confirmed that it expects to apply for regulatory approvals for a label indication expansion for semaglutide 2.4 mg (Wegovy) in the US and EU in 2023.
After the strong revaluation of the shares of Novo Nordisk this Tuesday, the market capitalization of the Danish pharmaceutical company has climbed to consolidate itself as the second largest company in Europe by market value, only behind the French LVMH.
According to the Scandinavian company, the trial achieved its primary objective by demonstrating a statistically significant and greater reduction in major adverse cardiovascular events (MACE) of 20% for people treated with semaglutide 2.4 mg compared to placebo.
Likewise, the Danish pharmacist highlighted that, in the trial, semaglutide 2.4 mg appeared to have a safe and well-tolerated profile in line with previous trials.
“People with obesity are at increased risk of cardiovascular disease, but to date, there are no approved weight-control medications that have been shown to provide effective weight control while reducing the risk of heart attack, stroke or cardiovascular death. Therefore, we are very excited about the results of SELECT,” said Martin Holst Lange, Executive Vice President of Development at Novo Nordisk.
“SELECT is a landmark trial and has shown that semaglutide 2.4 mg has the potential to change the way obesity is viewed and treated.”
